[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"macular-edema\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:macular-edema":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,40,65,105,136,165,193,223],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100590086","phase-2-a-study-to-test-whether-bi-1815368-helps-people-with-an-eye-condition-called-diabetic-macular-edema-100590086",false,"NCT06962839","A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema","A Randomised, Double-masked, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Oral BI 1815368 in Participants With Centre-involved Diabetic Macular Edema for 48 Weeks of Treatment (THULITE)","Inclusion criteria:\n\n* ≥18 years of age\n* Diagnosis of diabetes mellitus (DM) (type 1 or type 2), Haemoglobin A1C (HbA1c) \\\u003C12% treated with stable medication for at least 30 days prior to Day 1; no already-set plans for major changes in DM medication (e.g. start of new medication) at the time of screening and baseline\n* Centre-involved diabetic macular edema (CI-DME) confirmed on spectral domain optical coherence tomography (SD-OCT) with central subfield foveal thickness (CST) ≥320 µm in the study eye at screening\n* Best corrected visual acuity (BCVA) visual acuity Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in the study eye between 24 and 78 (Snellen equivalent range 20\u002F320 to 20\u002F32) at screening Further inclusion criteria apply.\n\nExclusion criteria:\n\n* Macular edema considered to be due to other causes than CI-DME in the study eye\n* Proliferative diabetic retinopathy or iris neovascularisation (including the anterior chamber angle) in the study eye\n* Any intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) treatment within 4 months before Day 1 (other than faricimab or aflibercept 8mg), and within 6 months before Day 1 for faricimab or aflibercept 8 mg, and\u002For more than 4 prior IVT injections with anti-VEGF treatment in total in the study eye\n* Any history of panretinal photocoagulation, macular laser photocoagulation, vitreoretinal surgery, IVT or periocular corticosteroid treatment (within 12 months before Day 1), history of fluocinolone ophthalmic implant or dexamethasone IVT implant before Day 1, or topical steroid or NSAID treatment (within 30 days before Day 1)\n* Active ocular inflammation of any history of intraocular inflammation within 1 year\n* Aphakia or total absence of the posterior capsule; Yttrium aluminium garnet (YAG) laser capsulotomy in the study eye is permitted if more than 2 months prior to Day 1 Further exclusion criteria apply.","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is open to adults 18 and older with an eye condition called diabetic macular edema. People are required to have a specific type of diabetic macular edema called centre-involved diabetic macular edema (CI-DME) to take part. The purpose of this study is to find out whether a medicine called BI 1815368 improves sight in people with CI-DME and to find the most suitable dose.\n\nThis study has 2 parts. In the first part, participants are put into 2 groups of equal size randomly, which means by chance. One group takes BI 1815368 tablets and the other group takes placebo tablets. Placebo tablets look like BI 1815368 tablets but do not contain any medicine. In the second part, participants are put into 4 groups of equal size randomly. 3 groups take different daily doses of the study medicine, BI 1815368, while 1 group takes placebo. All participants take tablets twice a day for about 11 months.\n\nParticipants are in the study for about 1 year. During this time, they visit the study site 16 times. At visits, doctors check the participant's vision and collect information on any health problems. They take detailed pictures of the eye. The changes over time are compared between the groups to see if the treatment works.",[26],"Macular Edema","RECRUITING","2026-06-23",{"date":30,"type":31},"2026-06-24","ACTUAL",{"date":33,"type":31},"2025-06-05",{"date":35,"type":20},"2027-09-29",{"name":37,"class":38},"Boehringer Ingelheim","INDUSTRY",80,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":64},"100579546","phase-2-safety-tolerability-and-efficacy-of-intravitreal-kio-104-in-patients-with-macular-edema-100579546","NCT06825702","Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema","A Phase 2, Open-label, Multiple Dose Study of the Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema (KLARITY-1)","KLARITY-1","Inclusion Criteria:\n\nParticipants must meet all the following criteria:\n\n1. Be aged 18 to 85 years inclusive at the time of consent.\n2. Provide informed consent prior to any study procedures, as stipulated by local laws, Ethics Committee (EC) and Regulatory Authority (RA) guidelines.\n3. Be willing and able to follow all study instructions, attend all study visits, and complete all study assessments.\n4. Have a clinical diagnosis of ME in the study eye secondary to non-infectious uveitis, retinal vein occlusion, diabetic retinopathy or cataract surgery.\n5. If currently receiving systemic corticosteroid therapy or immunosuppressive therapy (or any combination thereof), be on a stable dose of therapy for at least 3 months prior to Screening and during the study.\n6. Have a Central Subfield Thickness (CST) of ≥ 350 μm.\n7. Have a Best Corrected Visual Acuity (BCVA) in the study eye of:\n\n   1. ≤ 20\u002F32 (6\u002F9.5); logMAR ≥ 0.2; ≤ 75 ETDRS letters\n   2. ≥ 20\u002F800 (6\u002F240); logMAR ≤ 1.6; ≥ 5 ETDRS letters\n8. Have media clarity and pupillary dilation sufficient for adequate visualization and assessment of the study eye.\n9. Be willing to avoid disallowed medications and treatments for the duration of the study.\n10. Agree to follow appropriate contraception requirements from screening until 3 months after the last dose of the study drug.\n\n    1. Participants assigned female at birth who are of child-bearing potential (OCBP) must agree to a pregnancy test at Screening and prior to each dose of investigational medicinal product (IMP) and use an acceptable method of birth control including oral, transdermal, injectable, or implantable hormonal contraception, intrauterine device, abstinence from intercourse with partner assigned male at birth, or surgical sterilisation of partner assigned male at birth.\n    2. Participants assigned female at birth are not OCBP if they have had a hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or are post-menopausal by at least 12 months. Post-menopausal status of amenorrheic female participants should be confirmed at Screening through testing of follicle-stimulating hormone (FSH) as per analysing laboratory threshold.\n    3. Participants assigned male at birth with a partner OCBP must be surgically sterile for at least 3 months prior to starting study drug, or ensure their partner uses contraception as outlined above, and must use a male condom. Participants assigned male at birth must not donate sperm from Screening until 3 months after the last dose of IMP.\n    4. Participants who have practiced true abstinence for at least 1 year due to usual and preferred lifestyle choice are exempt from contraceptive requirements. If a participant who is abstinent becomes sexually active, they must agree to use appropriate contraception as described above.\n\nExclusion Criteria:\n\nParticipants must not meet any of the following criteria:\n\n1. Have media opacities (cornea, anterior or posterior synechia, cataract, vitreous haze and others) of either eye that preclude investigation and documentation of the posterior pole and intravenous fluorescein angiography, or optical coherence tomography evaluation in the study eye.\n2. Receive local or systemic biologicals (i.e. tumour necrosis factor \\[TNF\\]-blockers, B-cell blockers, cytokines, cytokine-blockers, receptor antagonists) 90 days prior to Day 1 or planned during the study.\n3. Receive treatment with cyclophosphamide or chlorambucil during the study.\n4. Receive intravitreal injections (including but not limited to anti-vascular endothelial growth factors) 90 days prior to Day 1 or planned during the study.\n5. Receive a posterior subtenon's or orbital floor injection of steroids 90 days prior to Day 1 or planned during the study.\n6. Have any implantable corticosteroid-eluting device (Ozurdex, Iluvien, Retisert, triamcinolone intravitreal implant, fluocinolone intravitreal implant) in the study eye, with the following exceptions:\n\n   1. If the device had been removed more than 90 days prior to Day 1 of the study.\n   2. If Ozurdex® had been implanted at least 6 months before Day 1 of the study.\n   3. If Iluvien® or Retisert® had been implanted at least 3 years before Day 1 of the study.\n   4. Use of topical steroids are permissible provided the participant is receiving a stable dose for at least 3 months prior to Screening and during the study.\n7. Have ocular surgery (including cataract extraction, laser surgery such as pan retinal photocoagulation, vitreoretinal or scleral buckling surgery) in the study eye, within 90 days prior to Day 1, or planned during the study.\n8. Have a capsulotomy in the study eye, within 30 days prior to Day 1, and during the study.\n9. Have Intraocular pressure (IOP) ≥ 25 mmHg in the study eye (glaucoma patients maintained on no more than one topical medication with IOP \\\u003C 25 mmHg are allowed to participate).\n10. Have ocular hypotony (IOP \\\u003C 6 mmHg) in the study eye.\n11. Have aphakia or anterior chamber lens in the study eye.\n12. Have visible scleral thinning, scleral ectasia or keratoconus in the study eye.\n13. Have presence of any ocular malignancy in either eye.\n14. Have evidence of any other clinically significant ocular disease that might interfere with the study assessments.\n15. Have ocular or periocular (either eye) or systemic infection and\u002For a temperature greater than 38.0°C, or the use of systemic or topical ocular antibiotics within 14 days of Day 1.\n16. Have a psychiatric condition that, in the Investigator's opinion, precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder; disorder requiring lithium; or within five years prior to screening, a history of suicide plan.\n17. Have any clinically significant abnormality at screening determined by medical and ophthalmic history, vital signs, clinical biochemistry, hematology, urinalysis, or a 12-lead electrocardiogram (ECG), as assessed by the Investigator, which might interfere with the study assessments or the ability of the participant to complete the study.\n18. Have any other medical condition or significant co-morbidities, or any finding during screening, which in the view of the Investigator is likely to interfere with the study or put the participant at risk, confound study data, or interfere significantly with study participation.\n19. Have participated in any other investigational drug or device clinical trial within 90 days prior to Day 1 or planning to participate in other investigational drug or device clinical trials during the study and within 120 days following Day 1. This includes both ocular and non-ocular clinical trials.\n20. Have any clinically significant clotting abnormality as assessed by the Investigator, which might interfere with the collection of blood samples required by the study.\n21. Have a known allergy or hypersensitivity to the study medication, any component of the delivery vehicle, any corticosteroids, any diagnostic agents used during the study (e.g., fluorescein, dilation drops), or any other standard of care medications likely to be used during the study (e.g., antibiotic drops, povidone, rescue medications).\n22. Be pregnant or breast-feeding, or plan to become pregnant during the study.","85 Years",{"count":50,"type":20},28,[23],"This is a multi-center, open label study to assess the safety, tolerability, and efficacy of KIO-104 administered by IVT injection to the study eye of eligible participants with macular edema.",[26],[26],"2026-06-14",{"date":57,"type":31},"2026-06-16",{"date":59,"type":31},"2025-05-01",{"date":61,"type":20},"2026-12",{"name":63,"class":38},"Kiora Pharmaceuticals, Inc.",6,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":104},"100372409","high-resolution-high-speed-multimodal-ophthalmic-imaging-100372409","NCT04129021","High Resolution, High-speed Multimodal Ophthalmic Imaging","High Resolution and High Speed Multimodal Ophthalmic Imaging","IMA-MODE","Inclusion Criteria:\n\n* People over 18\n* Patient with a pathology affecting the eye or healthy volunteer\n* Participant who signed the consent\n* Beneficiaries of the health insurance\n\nExclusion Criteria:\n\n* Patients with a history of photosensitivity.\n* Patients who have just received a photodynamic therapy treatment (\n* Patients taking drugs with photosensitivity as a side effect.\n* Persons with pacemakers or other implanted electronic medical device\n* Patients with viral conjunctivitis or any other infectious disease.\n* Patients with skin lesions on the neck or forehead\n* Patients at high risk of damage from optical radiation, such as aphakic patients, or patients with decreased sensitivity to light due to fundus disease.\n* Pregnant or lactating women\n* Participant unable to be followed throughout the study\n* Vulnerable people\n* Subjects with predisposition to closure of the iridocorneal angle",true,{"count":75,"type":20},1200,[77],"NA","Knowledge of the pathogenesis of ocular conditions, a leading cause of blindness, has benefited greatly from recent advances in ophthalmic imaging. However, current clinical imaging systems are limited in resolution, speed, or access to certain structures of the eye.\n\nThe use of a high-resolution imaging system improves the resolution of ophthalmoscopes by several orders of magnitude, allowing the visualization of many microstructures of the eye: photoreceptors, vessels, nerve bundles in the retina, cells and nerves in the cornea.\n\nThe use of a high-speed acquisition imaging system makes it possible to detect functional measurements such as the speed of blood flow. The combination of data from multiple imaging systems to obtain multimodal information is of great importance for improving the understanding of structural changes in the eye during a disease.\n\nThe purpose of this project is to observe structures that are not detectable with routinely used systems.",[80,81,82,26,83,84,85,86,87,88,89,90,91,92,93],"Retinitis Pigmentosa","Maculopathy, Age Related","Macular Dystrophy","Retinal Detachment","Retinal Degeneration","Glaucoma","Vascular Inflammation","Hypertension","Stroke","Diabetes","Corneal Dystrophy","Keratoconus","Dry Eye","Trauma","2025-11-17",{"date":96,"type":31},"2025-11-18",{"date":98,"type":31},"2019-07-03",{"date":100,"type":20},"2027-07",{"name":102,"class":103},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","OTHER",1,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":116,"conditions":117,"keywords":122,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100376893","phase-1-ms-553-in-diabetic-retinopathy-patients-with-central-involved-macular-edema-100376893","NCT04187443","MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema","A Multicenter, Open-label, Dose Escalation Study Assessing the Safety and Treatment Effects of MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema","Inclusion Criteria:\n\n* Diagnosis of diabetes mellitus (type 1 or type 2) according to ADA or WHO diabetic diagnosis criteria\n* Subject has the ability to follow the study instructions and is likely to complete all required study procedures and visits;\n* All males and females must consent to pregnancy prevention during the study and qualified measures of birth control. All females of childbearing potential must consent to a pregnancy test before entering the study.\n* Presence of central involved macular edema associated with diabetic retinopathy, i.e. diabetic macular edema (DME), as assessed by spectral domain optical coherence tomography (sd-OCT) of the central retina subfield thickness (CRT) at the Screening Visit (Centration must be confirmed by Investigators with signatures);\n* Best Corrected Visual Acuity (BCVA) score ≥ 34 letters (approximately 20\u002F200 to 20\u002F20 Snellen equivalent or better) using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity protocol, and assessed at the Screening Visit Visual acuity (VA);\n* Confirmation by the investigator that laser photocoagulation and anti-VEGF treatments are either declined by the patients or not needed and can be withheld for at least 3 months after the Screening Visit;\n* Ocular media and pupil dilation adequate to permit good quality retinal imaging as assessed at Screening Visit.\n\nExclusion Criteria:\n\n* Subjects with unstable metabolic or blood pressure control\n* Subject with emaciation or obesity at Screening Visit: body mass index (BMI) \\\u003C18.5kg\u002Fm2 or \\>28kg\u002Fm2\n* Current use or likely need for medications know to be toxic to the lens, retina or optic nerve, including Deferoxamine, Chloroquine \u002F hydroxychloroquine (Plaquenil), Tamoxifen, Phenothiazines and Ethambutol -\n* History of myocardial infarction or other cardiac event requiring hospitalization (unstable angina pectoris, etc.), cerebrovascular accident, transient ischemic attack, treatment for acute congestive heart failure or any arrhythmia within 4-months prior to Screening Visit;\n* Any situation that may in the opinion of the investigator preclude the safe administration of the study medication, adherence to the scheduled study visits, safe participation in the study or affect the results of the study as assessed at Screening Visit;",{"count":113,"type":20},45,[115],"PHASE1","This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema. Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts and will receive oral administration of MS-553 for 8 weeks.",[118,26,119,120,121],"Diabetic Macular Edema","Type 2 Diabetes With Diabetic Macular Edema","Type 1 Diabetes With Diabetic Macular Edema","Diabetic Retinopathy",[118,26,123,124,125,121],"Center-involved Diabetic Macular Edema","Center-involved DME","DME","2025-09-23",{"date":128,"type":31},"2025-09-29",{"date":130,"type":31},"2020-06-02",{"date":132,"type":20},"2026-12-30",{"name":134,"class":38},"Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.",3,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":104},"100539559","phase-3-a-efficacy-and-safety-study-of-ranibizumab-10mgml-injection-incepta-in-patients-with-diabetic-macular-edema-100539559","NCT06305416","A Efficacy and Safety Study of Ranibizumab 10mg\u002Fml Injection (Incepta) in Patients With Diabetic Macular Edema","Randomized, Double-blind, Parallel, Active Controlled Study to Compare Efficacy & Safety Between Ranibizumab 10mg\u002Fml Injection of Incepta and Lucentis in Patients With Diabetic Macular Edema by ITV Injection","Inclusion Criteria:\n\n1. Ages Eligible for Study: ≥ 18 Years\n2. Ability to provide written informed consent and comply with study assessments for the full duration of the study\n3. Diagnosis of diabetes mellitus (type 1 or 2). Any one of the following will be considered to be sufficient evidence that diabetes is present: Laboratory reports that prove DM of patient or current regular use of insulin for treatment of diabetes or current regular use of oral anti-hyperglycemic agent for the treatment of diabetes.\n4. Clinical evidence of retinal thickening due to macular edema involving the center of the macula (can be associated with diabetic retinopathy)\n5. Central diabetic macular edema present on clinical examination and OCT testing with central 1mm sub field thickness greater than 300 microns as measured on -OCT\n6. Visual acuity score greater than or equal to 19 letters (20\u002F400) and less than or equal to 73 letters (20\u002F40) by the ETDRS\u002F Snellen chart visual acuity protocol\n7. Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography\n8. Willingness and ability to undertake all scheduled visits and assessments\n\nExclusion Criteria:\n\n1. Prior treatment with any Intravitreal drug, Bevacizumab, verteporfin or photodynamic therapy (except for extra foveal laser photocoagulation) in the study eye within past 3 months before study entry\n2. Laser photocoagulation in the study eye within 1 month before study entry\n3. Participation in another ocular investigation or trial simultaneously\n4. Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal women not using adequate contraception.\n5. Blood pressure \\> 160\u002F100 mmHg (systolic above 160 or diastolic above 100) and Random Blood Sugar (RBS) ≥ 12 mmol\u002FL and\u002F or HbA1c ≥ 7.5%\n6. Evidence of vitreoretinal interface abnormality and optic nerve disease after ocular exam or OCT that may be contributing to the macular edema\n7. Any concurrent intraocular condition in the study eye that could either require medical or surgical intervention during the study period or that could contribute to a loss of best corrected visual acuity over the study period (e.g. cataract that might decrease the vision by 3 or more lines, uncontrolled glaucoma, uveitis, previous corneal transplant etc.). The decision regarding exclusion is to be based on the opinion of the investigator.\n8. An eye that, in the investigator's opinion, has no chance of improving in visual acuity following resolution of macular edema (e.g. presence of sub retinal fibrosis or geographic atrophy).\n9. Presence of suspected ocular or periocular infections, another ocular condition that may affect the visual acuity or macular edema during the course of the study (uveitis, Irvine-Gas)\n10. Vitreous hemorrhage preventing visualization of retina\n11. History of vitreous surgery, cataract surgery, YAG capsulotomy in the study eye within last 3 months of enrolment\n12. Visual acuity \\\u003C20\u002F400 in the fellow eye\n13. Known hypersensitivity to Ranibizumab or any of the components of study medication\n14. History of cerebral vascular accident or myocardial infarction within past 3 months.\n15. Employees of Investigational sites, individuals directly involved with the conduct of the study or immediate family members thereof, prisoners, and persons who are legally institutionalized.\n16. Current use of systemic medications known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine\u002F hydroxychloroquine, tamoxifen, phenothiazine, vigabatrin and ethambutol, and such medications will not be allowed during the study period.",{"count":144,"type":20},70,[146],"PHASE3","Macular edema in diabetes, defined as retinal thickening within two disc diameters of the center of the macula, results from retinal microvascular changes that compromise the blood-retinal barrier, causing leakage of plasma constituents into the surrounding retina and consequently retinal edema. Thickening of the basement membrane and reduction in the number of pericytes are believed to lead to increased permeability and incompetence of the retinal vasculature. This compromise of the blood-retinal barrier leads to the leakage of plasma constituents into the surrounding retina with subsequent retinal edema. Hypoxia produced by this mechanism can also stimulate the production of vascular endothelial growth factor (VEGF). Vascular endothelial growth factor (VEGF) increases retinal vascular permeability, causes breakdown of the blood-retina barrier and results in retinal edema.\n\nDiabetic macular edema (DME) is the most common cause of visual reduction in patients with Diabetes Mellitus. The prevalence of DME globally is around 6.8 %. Diabetic Retinopathy (DR) is the most common microvascular complication of diabetes and the leading cause of blindness worldwide. DME is a complication of diabetic retinopathy that affects the macula, which is located at the center of the retina and responsible for central vision. Bangladesh is the 10th country in the world for the number of adults living with diabetes with some 7.1 million (5.3-12.0). In Bangladesh, it is therefore expected that diabetic secondary complications, like DR, will increase along with the rising trend of diabetes mellitus.\n\nThe use of therapeutic monoclonal antibodies has revolutionized in the treatment of many diseases. In recent years, millions of patients have been successfully treated with these biological agents. Ranibizumab is one such therapeutic monoclonal antibody for intraocular use. Ranibizumab is a humanized, recombinant, immunoglobulin G1 monoclonal antibody fragment against vascular endothelial growth factor A (VEGF-A) and thus prevents choroidal neovascularization. The small size of ranibizumab allows for enhanced diffusion into the retina and choroid.",[118,121,26,149,150,84],"Macular Degeneration","Retinal Disease",[152,153,89,154,155],"Ranibizumab","Efficacy","Retina","Edema","2025-06-03",{"date":158,"type":31},"2025-06-06",{"date":160,"type":31},"2024-03-30",{"date":162,"type":20},"2025-12",{"name":164,"class":38},"Incepta Pharmaceuticals Ltd",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":180,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":104},"100514257","micropulsed-laser-in-patients-with-macular-oedema-in-retinal-dystrophies-100514257","NCT05976139","Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies","Treatment of Macular Oedema in Patients With Hereditary Retinal Dystrophies by Applying the Micropulsed Subthreshold Laser","Inclusion Criteria:\n\n* Patients with inherited retinal disease\n* Age between 18 and 80 years\n* Conclusive molecular genetic study for IRD\n* Male or female patient\n* Presence of macular oedema assessed by sd-OCT with reduction ≤ 20% after 3 months of diuretics or draining supplements or 4 months after last anti-VEGF or steroid injection\n* Phakic and pseudophakic patients\n* Central Retinal thickness \\> 320 microns in men and \\> 305 microns in women\n* Informed consent freely granted and acquired before the start of the study\n* Participant has the ability to understand and willingness to follow study instructions and is likely to complete all required visits and procedures.\n\nExclusion Criteria:\n\n* Patients with cataract extraction prior to 6 months\n* Patients with IOP ≥ 20 mmHg\n* Patients with a clinical diagnosis of retinal dystrophy of unproven genetic origin\n* Patients with diabetes\n* Patients with central serous chorioretinosis, retinal vein occlusion, age-related degeneration\n* Patients with current or previous vitreo-retinal pathology or with indication for vitreo-retinal surgical therapy (tractional oedema)\n* Patients with a lack of target fixation at 32 cm\n* Pregnant women","80 Years",{"count":174,"type":20},10,[77],"The purpose of this study is to investigate whether subthreshold treatment with micropulsed laser can be effective in resolving macular edema in patients with inherited retinal dystrophy.\n\nVisits will be performed after 1, 3, 6, 9, 12, 18, and 24 months after treatment. Laser treatment will be performed on the day of the first visit, and its repetition at subsequent visits between months 3 and 12 will be evaluated.\n\nEvaluations of treatment effects will include:\n\n* comprehensive ophthalmologic examination\n* multifocal electroretinogram\n* OCT examination\n* OCT-angiography examination\n* retinography\n\nPrimary endpoint.\n\n\\- central retinal thickness, measured by OCT",[26,178,179],"Inherited Retinal Dystrophy","Laser Retinopathy",[181,182,183,26],"Visual Acuity","Retinal Function","IRD","2025-02-26",{"date":186,"type":31},"2025-02-28",{"date":188,"type":31},"2023-09-06",{"date":190,"type":20},"2025-07-30",{"name":192,"class":103},"Fondazione G.B. Bietti, IRCCS",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":201,"phases":4,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":135},"100169926","mechanical-properties-of-the-internal-limiting-membrane-and-intraoperative-utility-of-brilliant-blue-g-bbg-and-indocyanine-green-icg-assisted-chromovitrectomy-100169926","NCT01485575","Mechanical Properties of the Internal Limiting Membrane and Intraoperative Utility of Brilliant Blue g (Bbg) and Indocyanine Green (Icg) Assisted Chromovitrectomy","Inclusion Criteria:\n\n* Over 18 Years of age\n* No other chromovitrectomy in previous 6 months\n* Only one of three vitaly dyes used intraoperatively (BBG, ICG or TB)\n\nExclusion Criteria:\n\n* Previous chromovitrectomy during last 6 months\n* Pregnant patients\n* Patients under 18 years of age",{"count":200,"type":20},50,"OBSERVATIONAL","Intravitreal dyes are intended to make the surgical extraction of the Internal limiting membrane (ILM) safer and more complete. However, the search for an adequate vitaly dye is ongoing. The most commonly used vital dye is Indocyanine green (ICG), although it is not approved for intravitreal use and has been associated with ocular toxicity. The reason for its continued popularity seems to be that it stains the ILM better than the approved and less toxic alternative substances Brilliant Blue G (BBG) and Trypan blue (TB). According to anecdotal reports from surgeons, another reason for ICGs popularity may be the fact that it seems to make ILM removal easier. Ultimately, the intention of the investigators research is to identify possible modifications to existing dyes to reach improved intraoperative dye utility combined with a favorable safety profile.\n\nProtocol was amended and approved concerning additional use of basal membrane of deceased donors.",[26],[205,206,207,208,209,210,211,212,213],"Chromovitrectomy","Indocyanine green","ICG","Brilliant Blue G","BBG","Trypan blue","TB","Internal limiting membrane","ILM","2025-02-10",{"date":216,"type":31},"2025-02-13",{"date":218,"type":4},"2011-11",{"date":220,"type":20},"2028-06",{"name":222,"class":103},"University Hospital, Basel, Switzerland",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":230,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":21,"phases":233,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":104},"100561837","phase-2-efficacy-and-safety-of-intravitreal-injection-of-bevacizumab-with-and-without-oral-curcumin-100561837","NCT06595355","Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin","Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin in Diabetic Macular Edema","Inclusion Criteria:\n\nPatients with center-involving macular edema with macular center thickness more than 300 microns in OCT 2-Patients who did not receive intravitreal bevacizumab in the last 3 months and intravitreal corticosteroids in the last 6 months.\n\n3- The amount of BCVA should not be \\\u003C20\u002F400. 4-Consent to participate in the study\n\nExclusion Criteria:\n\n1. Other retinal diseases except for DME and macular edema due to other causes including uveitis, epiretinal membrane, central retinal vein occlusion, and...\n2. Existence of proliferative diabetic retinopathy and patients with a history of vitrectomy\n3. Patients with glaucoma, vitreous hemorrhage, age-related macular degeneration (ARMD)\n4. Media opacities that limit the interpretation of diagnostic tests\n5. Surgery or procedure 3 months before starting treatment\n6. Pregnancy or breastfeeding\n7. History of allergy to curcumin\n8. Use of warfarin\n9. Changing the patient's clinical diagnosis or the need for surgical interventions in the course of the disease\n10. Change in the patient's general health condition\n11. Absence of patient referrals\n12. Lack of consent to continue treatment and follow-up","40 Years",{"count":232,"type":20},52,[23,146],"The purpose of this study is to evaluate the effectiveness of adding curcumin oral treatment to bevacizumab intravitreal injection in patients with central macular edema.\n\nA blind study and a randomized and controlled clinical trial are conducted on diabetic patients with macular edema. The patients are divided into two intervention groups (bevacizumab + curcumin) and control (bevacizumab + placebo).\n\nThe evaluation of the central thickness of the macula and the evaluation of the central volume of the macula are the primary goals and the evaluation of the best visual acuity of the patient is the secondary goal.",[118,26,236],"Retinal Neovascularization",[238,239,240,241,121,236],"macular edema","diabetic macular edema","central macular edema","bevacizumab","2024-09-10",{"date":244,"type":31},"2024-09-19",{"date":246,"type":31},"2021-10-10",{"date":248,"type":20},"2025-09-22",{"name":250,"class":103},"Isfahan University of Medical Sciences"]